超声融合导航技术指导微波消融治疗小肝癌临床价值研究*

doi:10.3969/j.issn.1672-5069.2022.05.023

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (5): 698-701.doi: 10.3969/j.issn.1672-5069.2022.05.023

超声融合导航技术指导微波消融治疗小肝癌临床价值研究^*

李季, 周仲松, 郜玉峰, 薛继华, 张骏飞

230022 合肥市安徽医科大学第一附属医院感染病科

收稿日期:2022-04-29 出版日期:2022-09-10 发布日期:2022-09-22
通讯作者: 张骏飞,E-mail: zhangjunfei105@aliyun.com
作者简介:李季,男,38岁,大学本科,主治医师。主要从事肝癌的影像学诊断和微波消融治疗研究。E-mail: 274343012@qq.com
基金资助:
安徽省中央引导地方科技发展项目(编号:201907d0750008);安徽省自然科学基金青年基金资助项目(编号:1608085QH172);合肥市借转补基金项目(编号:J2019Y04)

Short-term clinical efficacy of microwave ablation under the guidance of ultrasound fusion imaging in the treatment of patients with small primary liver cancer

Li Ji, Zhou Zhongsong, Gao Yufeng, et al.

Department of Infectious Diseases, First Affliated Hospital, Anhui Medical University, Hefei 230022, Anhui Province, China

Received:2022-04-29 Online:2022-09-10 Published:2022-09-22

摘要/Abstract

摘要： 目的研究应用超声融合导航技术在常规超声检查显示困难的小肝癌患者引导微波消融(MWA)治疗的价值。方法 2018年1月～2022年1月我院诊治的80例原发性肝癌(PLC)患者,其中接受经皮肝动脉导管化疗栓塞术(TACE)治疗40例,接受在超声融合导航技术指导下MWA治疗40例,术后随访。采用ELISA法检测血清甲胎蛋白(AFP)和热休克蛋白-90(Hsp-90)水平。结果在治疗后1个月复查,MWA治疗组完全缓解率为82.5%,显著高于TACE治疗组的37.5%,差异有统计学意义(P<0.05);在治疗后3个月,MWA治疗组血清AFP和Hsp90水平分别为(15.2±9.3)μg/L和(63.5±7.8)ng/ml,显著低于TACE治疗组【分别为(32.6±10.2)μg/L和(88.4±9.1)ng/ml,P<0.05】; 术后,MWA治疗组肝区疼痛发生率为47.5%,显著低于TACE治疗组的82.5%,差异有统计学意义(P<0.05)。结论采用超声融合导航技术指导常规超声检查显示困难的小肝癌微波消融治疗可提高肝癌病灶完全消融率,减少术后不良反应,值得进一步研究。

关键词: 原发性肝癌, 融合影像导航, 微波消融, 经皮肝动脉导管化疗栓塞术, 治疗

Abstract: Objective The aim of this study was to investigate the short-term clinical efficacy of microwave ablation (MWA) under the guidance of ultrasound fusion imaging in the treatment of patients with small primary liver cancer (sPLC). Methods 80 patients with sPLC were admitted to our hospital between January 2018 and January 2022,and were divided into two groups,with 40 cases in each group. The patients in the observation group received MWA treatment under the ultrasound fusion imaging guidance, and those in the control group received transcatheter arterial chemoembolization (TACE). Serum alpha-fetoprotein (AFP) and hot-shock protein-90 (HSP-90) levels were assayed by ELISA. Results At the end of one month treatment, the complete response rate in MWA-treated patients was 82.5%, much higher than 37.5% in TACE-treated patients (P<0.05); at the end of three month treatment, serum AFP and HSP-90 levels in MWA-treated patients were (15.2±9.3)μg/L and (63.5±7.8)ng/ml, significantly lower than [(32.6±10.2)μg/L and (88.4±9.1)ng/ml, respectively, P﹤0.05] in TACE-treated patients; after operation, the incidence of local pain in MWA-treated patients was 47.5%, much lower than 82.5% in TACE-treated patients (P<0.05). Conclusions The application of MWA under the guidance of ultrasound fusion imaging in the treatment of patients with sPLC is efficacious, which could improve the complete ablation rate of lesions, and worthy of clinical verification.

Key words: Hepatoma, Microwave ablation, Transcatheter arterial chemoembolization, Ultrasound fusion imaging, Therapy

李季, 周仲松, 郜玉峰, 薛继华, 张骏飞. 超声融合导航技术指导微波消融治疗小肝癌临床价值研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 698-701.

Li Ji, Zhou Zhongsong, Gao Yufeng, et al.. Short-term clinical efficacy of microwave ablation under the guidance of ultrasound fusion imaging in the treatment of patients with small primary liver cancer[J]. Journal of Practical Hepatology, 2022, 25(5): 698-701.

参考文献

[1]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版).中华消化外科杂志,2022,21(2):143-168.
[2]Vogl TJ,Nour-E din NA,Hammersting RM,et al.Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms. Microwave ablation(MWA):grundlagen,technik und ergebnisse in primären und sekundären lebertumoren-Übersichtsarbeit.Rofo,2017,189(11):1055-1066.
[3]张静,郭长存.应用米兰标准微波消融治疗肝细胞癌患者预后及其影响因素分析.实用肝脏病杂志,2020,23(6):873-876.
[4]Zhang K,Liu M,Xu Y,et al.Multiparametric magnetic resonance-guided and monitored microwave ablation in liver cancer.J Cancer Res Ther,2020,16(7):1625-1633.
[5]Rai P,Dakua S,Abinahed J,et al.Feasibility and efficacy of fusion imaging systems for immediate post ablation assessment of liver neoplasms:protocol for a rapid systematic review.Int J Surg Protoc,2021,25(1):209-215.
[6]王婵,沈长清,吴晓琼,等.表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析.实用肝脏病杂志,2022,25(2):259-262.
[7]Dou JP,Liang P,Yu J.Microwave ablation for liver tumors.Abdom Radiol(NY),2016,41(4):650-658.
[8]罗丽萍,颜荣华,李凯,等.超声融合成像技术辅助3～5cm肝癌热消融治疗的价值.中华超声影像学杂志,2019,35(4):318-322.
[9]Forner A,Ayuso C,Varela M,et al.Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable.Cancer,2010,115(3):616-623.
[10] Izzo F,Granata V,Grassi R,et al.Radiofrequency ablation and microwave ablation in liver tumors:an update.Oncologist,2019,24(10):e990-e1005.
[11] Hartley-Blossom Z,Alam M,Stone J,et al.Microwave ablation in the liver:an update.Surg Technol Int,2020,37:72-78.
[12] Ding J, Wang D, Zhou Y,et al.A novel mono-modality fusion imaging method based on three-dimensional contrast-enhanced ultrasound for the evaluation of ablation margins after microwave ablation of hepatocellular carcinoma.J Gastrointest Oncol,2021,12(1):184-195.
[13] Yu X,Liu F,Liang P,et al.Microwave ablation assisted by a computerised tomography-ultrasonography fusion imaging system for liver lesions: an ex vivo experimental study.Int J Hyperthermia,2011,27(2):172-179.
[14] Minami Y,Kudo M.Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.J Med Ultrason,2020,47(2):257-263.
[15] Long Y,Xu E,Zeng Q,et al.Intra-procedural real-time ultrasound fusion imaging improves the therapeutic effect and safety of liver tumor ablation in difficult cases.Am J Cancer Res,2020,10(7):2174-2184.
[16] Bo XW,Xu HX,Wang D,et al.Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.Br J Radiol,2016,89(1067):20160379.
[17] Ahmed Mohammed HF,Roberts LR.Should AFP (or any biomark-ers) be used for HCC surveillance? Drug Discov Ther,2017,11(3):168-169.
[18] Sun C, Bai M, Ke W,et al.The HSP90 inhibitor,XL888,enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.Life Sci,2021,282:119762.
[19] Dong L,Xue L,Zhang C,et al.HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma.Mol Med Rep,2019,19(1):524-532.
[20] Zhou X,Wen Y,Tian Y,et al.Heat shock protein 90α-dependent B-cell-2-associated transcription factor 1 promotes hepatocellular carcinoma proliferation by regulating MYC proto-oncogene c-MYC mRNA stability.Hepatology,2019,69(4):1564-1581.
[21] Zhou Y,Deng X,Zang N,et al.Transcriptomic and proteomic investigation of HSP90A as a potential biomarker for HCC.Med Sci Monit,2015,21:4039-4049.
[22] Asahina Y,Tsuchiya K,Nishinura T,et al.Alpha-fetoprotein levels after interferor therapy and risk of hepatocarconogenesis in chronic hepatitis C.Hepatolgy,2013,58(4):1253-1262.
[23] Chang L,Wang W,Jiang N,et al.Dexamethasone prevents TACE-induced adverse events:A meta-analysis.Medicine(Baltimore),2020,99(47):e23191.

超声融合导航技术指导微波消融治疗小肝癌临床价值研究^*

Short-term clinical efficacy of microwave ablation under the guidance of ultrasound fusion imaging in the treatment of patients with small primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	南月敏, 李佳峥. 肝硬化与感染[J]. 实用肝脏病杂志, 2022, 25(5): 609-611.
[2]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[3]	王玉珊, 孔银, 刘元元, 刘天府, 麻爱娣, 张亚萍, 李永芳, 张岭漪. 不同转换治疗策略对经治的低病毒血症慢性乙型肝炎患者疗效的影响:单中心回顾性研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 633-636.
[4]	徐欢, 谭钧元, 黄荷, 董丹丹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及其外周血单个核细胞TLR4和B7-H1表达变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 637-640.
[5]	王春莹, 屈耀宁, 乔炜, 刘静静, 胡颖辉. 恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 641-644.
[6]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[7]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.
[8]	樊顺克, 王贵罗, 伊晓燕. 七氟醚联合丙泊酚静-吸复合麻醉用于原发性肝癌根治术治疗经验介绍^*[J]. 实用肝脏病杂志, 2022, 25(5): 702-705.
[9]	张凯, 刘培培, 饶石磊, 王琦, 岳恺, 王旸, 杨峥, 张松. 三维适形放射治疗不同大体肿瘤体积的原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 710-713.
[10]	李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.
[11]	周宇, 耿进朝, 韩雪, 于建华, 回瑾, 李岩, 李微. 射频消融治疗原发性肝癌患者疗效评价^*[J]. 实用肝脏病杂志, 2022, 25(5): 718-721.
[12]	任文妍, 赵森, 庄琰, 杜森, 李秋实. 血液抽吸联合射频消融治疗肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 726-729.
[13]	方骏, 王安, 孙修勇, 孙春辉, 张炳远, 朱武晖. 三镜联合分期手术与腹腔镜手术治疗老年胆总管结石合并胆囊结石患者疗效对比研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 730-733.
[14]	迪力旦·纳斯尔, 赵亮, 尼加提江·艾比不拉, 排祖拉·沙拉依阿当. 胆肠Roux-en-Y吻合术留置皮下空肠盲袢治疗肝内胆管结石患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 734-737.
[15]	郭景龙, 石保昌, 张洪战. 胆肠Roux-en-Y吻合术联合留置皮下空肠盲袢取石治疗肝内胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 738-741.